Original Research Article

Clinical and electrophysiological correlation of peripheral neuropathy in newly diagnosed type 2 diabetes mellitus

Ashok K. Bhuyan, Sonali Appaiah*

Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India

Received: 15 April 2018
Accepted: 08 May 2018

*Correspondence:
Dr. Sonali Appaiah,
E-mail: sonaliappaiah2@gmail.com

ABSTRACT

Background: The study was undertaken to evaluate the prevalence of peripheral neuropathy in newly diagnosed type 2 Diabetes mellitus (DM) by clinical examination and nerve conduction study (NCS), and to correlate them with risk factors.

Methods: Eighty newly detected cases of type 2 DM of age ≥18 years attending Endocrinology Department of Gauhati Medical College and Hospital, Assam, India were evaluated. Grading of symptoms and signs was done using the Neuropathy Symptoms Score (NSS) and Neuropathy Disability Score (NDS) respectively followed by NCS. Neuropathy was diagnosed based on abnormal NSS, NDS or NCS.

Results: Prevalence of peripheral neuropathy was 68.75% based on abnormal NCS/NDS/NCS. The most common symptom was presence of paraesthesia in 70.9%, followed by weakness in lower limbs in 16.36%. The most common sign was impairment of vibration perception in 76.3%, followed by absent ankle reflex in 56.36%. Abnormal NCS finding was seen in 55% of patients with neuropathy. Of all the patients with neuropathy, only 2.5% had subclinical neuropathy that is abnormal NCS finding in absence of sign and symptoms. Peripheral neuropathy had significant association with age at diagnosis, presence of hypertension, fasting plasma glucose (FPG), HbA1c, serum creatinine and estimated glomerular filtration rate (eGFR) (p<0.05). On multiple linear regression analysis, only age at diagnosis and FPG were independently associated with neuropathy (p<0.05).

Conclusions: Patients with type 2 DM have a high prevalence of peripheral neuropathy at diagnosis and very few of them harbour subclinical neuropathy. This study has shown that clinical examination still remains the main tool for detection of neuropathy.

Keywords: Nerve conduction study, Neuropathy symptoms score, Neuropathy disability score, Peripheral neuropathy, Type 2 Diabetes mellitus

INTRODUCTION

Neuropathy has been defined as demonstrable disorder, either clinically evident or subclinical, that occurs in the setting of diabetes without other causes for peripheral neuropathy.1 Diabetic distal symmetrical sensory or sensory motor polyneuropathy (DSPN) is the most common manifestation affecting about 30% of community-based people with diabetes mellitus. The most common etiological risk factors associated with Diabetic peripheral neuropathy are poor glycaemia control, visceral obesity, duration of diabetes, height, hypertension, age, smoking, hypoinsulinemia and dyslipidemia.2

Peripheral neuropathy is one of most common long-term complications of diabetes and it is associated with significant morbidity and mortality.3,4 It accounts for
more hospitalizations than all the other diabetic complications combined; and it is responsible for 50% to 75% of non-traumatic amputations.\(^5\) In spite of the significant morbidities and high cost of therapy associated, neuropathy is grossly under diagnosed by both endocrinologists and nonendocrinologists. The true prevalence of diabetic neuropathy in different studies varies substantially, depending on specific diagnostic criteria and methods used to define neuropathy. In the United States, prevalence ranges from 5% to 100%\(^3\).\(^5\)\(^6\) This study was conducted to find the prevalence and risk factors of peripheral neuropathy in newly diagnosed Indian patients with type 2 Diabetes mellitus (DM).

**METHODS**

This cross-sectional study was done at Gauhati Medical College and Hospital, Guwahati, Assam from December 2016 to December 2017. Eighty (80) randomly selected patients of newly diagnosed type 2 DM attending Endocrinology OPD of Gauhati Medical College and Hospital were recruited for the study. Inclusion criteria included age ≥18 years and duration of diabetes ≥6 months at the time of presentation. Type 2 DM was diagnosed as per the American Diabetic Association 2018 guidelines.\(^7\) Patient with confounding causes of neuropathy like chronic renal failure, chronic liver disease, chronic airways disease, carcinoma, infections, critical illness, vitamin B12 deficiency and patients on drugs known to affect nerve function were excluded from the study. Informed written consent was obtained from all subjects.

A detailed medical history was taken, and complete clinical examination was done in all patients. Baseline measurements of blood pressure, height, weight and body mass index (BMI) were done. Symptoms among the patients were evaluated using the Neuropathy Symptom Score (NSS). All patients were asked whether they experienced paraesthesia in their legs. A description of burning, numbness, or tingling was assigned a score of 2, and fatigue, cramping, or aching was assigned a score of 1. If the patient described the symptoms as occurring in their feet, calves, and elsewhere, scores of 2, 1, and 0 were assigned, respectively. Nocturnal exacerbation of symptoms was scored as 2; exacerbation of symptoms during the day as well as night was scored as 1, and exacerbation of symptoms during the daytime alone was scored as 0. If the symptoms had ever woken the patient from sleep, a score of 1 was assigned.

The patients were asked if any manoeuvre could reduce their symptoms; walking was assigned a score of 2, standing 1, and sitting or lying down 0. Thus, the maximum symptom score was 9. A minimum score of 3 was taken as the cut off to label a patient to have clinical neuropathy. Severity of symptoms were graded as: mild (scores: 3–4), moderate (scores: 5–6), and severe (scores: 7–9).\(^8\) Similarly, the signs were graded using the Neuropathy Deficit Score (NDS). Examination of vibration (using a 128-Hz tuning fork), pin-prick sensation (using pin), temperature sensation (using warm and cool water filled test tubes), and Achilles tendon reflex (using a tendon hammer) were done. The 3 percepts were scored 0 if present and normal, and 1 if absent, reduced, or uncertain. On either side, the ankle reflex was scored 0 if present and normal, and 2 if absent. The maximum score was 10. A minimum score of 3 was taken as the cut off to label a patient to have clinical neuropathy. The severity of NDS graded as, mild (scores: 3–5), moderate (scores: 6–8), and severe (scores: 9–10).\(^8\)

Routine blood investigations including fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), HbA1c, serum creatinine and fasting lipid profile were done in all patients.

Estimated glomerular filtration rate (eGFR) was calculated using the MDRD (Modification of Diet in Renal Disease Study Equation) formula. Nerve conduction study (NCS) was done by conventional method with surface electrodes with limbs kept warm at a temperature of 38°C.

In present study, neuropathy was diagnosed if abnormality in any one of the three parameters i.e. NSS, NDS and NCS was present. Neuropathy was further divided into types based on Toronto Consensus Panel into Possible DSPN, Probable DSPN, Confirmed DSPN and Subclinical DSPN.\(^9\)

**Possible DSPN**

The presence of symptoms or signs of DSPN may include the following: symptoms- decreased sensation, positive neuropathic sensory symptoms (e.g., “asleep numbness,” prickling or stabbing, burning or aching pain) predominantly in the toes, feet, or legs; or signs—symmetric decrease of distal sensation or unequivocally decreased or absent ankle reflexes.

**Probable DSPN**

The presence of a combination of symptoms and signs of neuropathy including any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes.

**Confirmed DSPN**

The presence of an abnormality of nerve conduction and a symptom or symptoms, or a sign or signs, of neuropathy confirm DSPN. If nerve conduction is normal, a validated measure of small-fibre neuropathy (SFN) (with class 1 evidence) may be used.

To assess for the severity of DSPN, several approaches can be recommended: for example, the graded approach outlined above; various continuous measures of sum scores of neurologic signs, symptoms, or nerve test.
scores; scores of functions of activities of daily living; or scores of predetermined tasks or of disability.

**Subclinical DSPN**

The presence of no signs or symptoms of neuropathy are confirmed with abnormal nerve conduction or a validated measure of SFN (with class 1 evidence).10

**Statistical Analysis**

X2 test and Student’s t-test were applied to compare frequencies and means respectively. ‘One way between group ANOVA’ was used to find correlation of risk factors in mild, moderate and severe neuropathy. Multiple logistic regression model was used to find risk factors associated with peripheral neuropathy.

**RESULTS**

A total of 80 patients of newly diagnosed type 2 diabetes mellitus were evaluated. Mean age of diagnosis was 47.1(SD±12.05) years.

Hypertension was present in 23.75% (19) of the patients. Mean BMI was 23.8 (SD±2.8) kg/m2, 12% (15) were overweight (BMI 23-24.9 Kg/m2) and 24% (30) were obese (BMI ≥ 25Kg/m2). The mean±SD of HbA1c among the patients was 10.5±2.5, while the mean serum creatinine and eGFR were 0.79±0.19 mg/dl and 108±33.8ml/min/1.73m2 respectively. Lipid profile showed mean±SD levels of total cholesterol of 199±44 mg/dl, HDL of 35.3±8.9 mg/dl, LDL of 122.4±36 mg/dl and triglyceride of 207.7±90.6 mg/dl.

**Figure 3: Prevalence of neuropathy in study population.**

The overall prevalence of peripheral neuropathy among newly diagnosed type 2 diabetes mellitus patients was 68.75% (55) based on the presence of abnormal NSS or NDS or NCS.

**Figure 4. Type of neuropathy based on Toronto consensus panel.**

Neuropathy was further divided into types based on Toronto Consensus Panel into Possible DSPN, Probable, Confirmed and Subclinical DSPN. In present study 68.75 % (55) had Possible DSPN, 52.5% (42) had Probable DSPN, and 53.75% (43) had confirmed DSPN and 3.75% (3) had subclinical DSPN.

The most common symptom was the presence of paraesthesia like tingling, burning and numbness over
feet seen in 70.9% (39) followed by weakness in lower limbs seen in 16.36% (9).

![Figure 5: Presenting symptoms of subjects with neuropathy.](image1)

Abnormal NSS was seen in 48.75% (39) of the patients. The symptoms were found to be mild in 10.9% (6), moderate in 18 (32.7%) and severe in 15 (27.27%). The most common sign was the impairment of vibration perception in 76.3% (42), followed by absent ankle reflex in 56.36% (31). Impairment of touch was seen in 7.27% (4) and perception of temperature, pain and pressure sensation was affected in 5.45% (3) each.

Abnormal NDS was seen in 38.75% (31). The signs were found to be mild in 9.09% (5), moderate in 41.8% (23), severe in 5.54% (3). Absence of symptoms and absence of signs were seen in 29% (16) and 43.63% (24) patients respectively.

![Figure 6: Presenting SIGNS of subjects with neuropathy.](image2)

![Figure 7: Grading of severity of symptoms and signs by Neuropathy Symptom Score (NSS).](image3)

When comparing baseline characteristics of patients with and without neuropathy, age at diagnosis was higher with a mean (±SD) of 51.09 (±11.54) years in patients with neuropathy as compared to 38.76 (±8.57) years in patients without neuropathy and was statistically significant (p<0.05). Males were affected more than the females in both the groups, (65.45:34.55) and (56:44) in neuropathic and non-neuropathic groups respectively, although the difference was not statistically significant. Hypertension was seen in 30.9% of patients with neuropathy, whereas it was seen only in 8% in patients without neuropathy, with a p value of 0.007. Mean FPG was statistically higher at 221.1 (±82) mg/dl in patients with neuropathy as compared to 164.2 (±60.7) mg/dl in patients without neuropathy (p=0.0007). Similarly, the mean PPPG in patients with neuropathy (326 ± 93.2 mg/dl) was higher than the mean PPPG of the patients without neuropathy (270.3 ± 96.4 mg/dl), and the difference was statistically significant (p=0.019). HbA1c was significantly higher in patients with neuropathy at 11.1 ± (2.26%) compared to 9.2 (± 2.46%) in patients.
without neuropathy (p=0.0019). Serum creatinine was significantly lower (p=0.002) and eGFR was higher (p=0.0005) among patients without neuropathy. There is no significant difference in BMI and lipid parameters among the neuropathic and non-neuropathic groups as shown in Table 1.

Table 1: The baseline characteristics of patients with and without neuropathy.

| Parameter                          | With Neuropathy (NSS/NDS/NCS) | Without Neuropathy | P value |
|------------------------------------|-------------------------------|--------------------|---------|
| Number of patients                 | 55(68.75%)                   | 25(31%)            | 0.43    |
| Male                               | 36(65.45%)                   | 14(56%)            |         |
| Female                             | 19(34.55%)                   | 11(44%)            |         |
| Age (years)                        | 51.09 ± 11.54                | 38.76 ± 8.57       | 0.0000001 |
| BMI (kg/m²)                        | 23.98 ± 2.83                 | 23.57 ± 2.87       | 0.55    |
| Hypertension (%)                   | 17(30.9%)                    | 2(8%)              | 0.007   |
| Neuropathy symptoms duration (days) | 54.5± 57.4                  | -                  |         |
| NSS (Absent, Mild, Moderate, Severe) | 70.9 % (29%, 10.9%, 32.7%, 27.27%) | - |         |
| NDS (Absent, Mild, Moderate, Severe) | 81.8 % (43.63%, 9.09%, 41.8%, 5.54%) | - |         |
| FPG (mg/dl)                        | 221.1 ± 82.4                 | 164.2 ± 60.7       | 0.0007  |
| PPPG (mg/dl)                       | 326 ± 93.2                   | 270.3 ± 96.4       | 0.019   |
| HbA1C (%)                          | 11.1 ± 2.26                  | 9.2 ± 2.46         | 0.0019  |
| S creatinine (mg/dl)               | 0.83± 0.19                   | 0.69 ± 0.17        | 0.002   |
| eGFR (ml/min/1.73 m²)              | 99.2 ± 32.66                 | 126.6 ± 29.61      | 0.0005  |
| S Cholesterol (mg/dl)              | 198.56 ± 42.66               | 200.2 ± 50.48      | 0.88    |
| HDL (mg/dl)                        | 34.50 ± 9.26                 | 37.2 ± 8.24        | 0.19    |
| LDL (mg/dl)                        | 123.1 ± 31.44                | 122.4 ± 46.66      | 0.93    |
| VLDL (mg/dl)                       | 41.3 ± 16.75                 | 40.5 ± 20.12       | 0.86    |
| TG (mg/dl)                         | 206.8 ± 84.30                | 203 ± 100.70       | 0.86    |

NSS- Neuropathy Symptoms Score NDS-Neuropathy disability score, FPG- Fasting plasma glucose, PPPG-Post prandial plasma glucose, eGFR- Estimated glomerular filtration rate

However, on multiple linear on analysis, of all the variables only age at diagnosis and FPG were independently associated with peripheral neuropathy (p<0.05).

Figure 9: Subgroup analysis of mild, moderate and severe neuropathy by ‘one way between group Anova’, with statistically significant difference in FBS, between the groups (p<0.05).

Figure 10: Subgroup analysis of mild, moderate and severe neuropathy by ‘one way between group Anova’, with statistically significant difference in PPBS, between the groups (p<0.05).
Among the 80 newly diagnosed patients of type 2 diabetes mellitus, 55% (44) patients had abnormal NCS. Neuropathy was sensory in distribution in 13.6% (6), motor in 6.8% (3) and mixed in 79.54% (35). The aetiology of neuropathy was demyelinating in 15.9 % (7), axonal in 31.8% (14) and mixed in 52.27% (23).

Mean (±SD) of age at diagnosis was statistically higher in patients with positive NCS (54.2 ±9.79) years, as compared to 38.3 (±8.16) years in patients with negative NCS. Presence of hypertension and duration of symptoms correlated significantly (p<0.05) with positive NCS.

Clinical signs assessed by NDS was seen in a significantly higher number of individuals with abnormal NCS (90.9%) as compared to only 25% patients with normal NCS(p<0.05). Clinical symptoms assessed by NSS seen in 65.9% of patients with abnormal NCS, compared to 30.5% in patients with normal NCS (p<0.05).

### Table 2: The baseline characteristics of patients with and without abnormal NCS.

| Variable                   | NCS positive | NCS negative | P value |
|----------------------------|--------------|--------------|---------|
| No of patient              | 44 (55%)     | 36 (45%)     | <0.05   |
| Age                        | 54.2±9.79    | 38.3±8.16    | <0.05   |
| Sex                        |              |              | 0.25    |
| Male                       | 30 (68.1%)   | 20 (55.5%)   |         |
| Female                     | 14 (13.8%)   | 16 (44.4%)   |         |
| No. of patients with       |              |              | 0.054   |
| hypertension               | 14 (31.8%)   | 5 (13.8%)    |         |
| BMI Kg/m²                  | 23.85±2.88   | 23.75±2.80   | 0.86    |
| Duration neuropathy        |              |              | 0.001   |
| symptoms (days)            | 60.68±62.55  | 10.83±17.7   |         |
| NSS                        |              |              | <0.05   |
| 25 (65.9%)                 | 11 (30.5%)   |             |
| NDS                        | 40 (90.9%)   | 9 (25%)      | <0.05   |
| FPG                        | 240±81.6     | 159.80±53.33 | <0.05   |
| PPPG                       | 352.8±90.9   | 259.61±82.55 | <0.05   |
| HbA1C                      | 12±1.76      | 8.80±2.14    | <0.05   |
| S creatinine               | 0.88±0.18    | 0.66±0.14    | <0.05   |
| eGFR (ml/min/1.73m²)       | 89.85±21.79  | 130.35±32.69 | <0.05   |
| S. cholesterol             | 205.31±39.65 | 191.33±50.17 | 0.17    |
| HDL                        | 34.09±9.39   | 36.91±8.35   | 0.15    |
| LDL                        | 126.47±31.15 | 117.55±42.66 | 0.29    |
| VLDL                       | 43.68±17.51  | 38.82±18.58  | 0.23    |
| TG                         | 218.59±88.27 | 194.47±93.005 | 0.24   |

Similarly mean FPG, PPPG, HbA1c, serum creatinine was significantly higher (p<0.05) and eGFR was significantly lower (p<0.05) in patients with positive NCS finding. There is no significant difference in BMI and lipid parameters among the patients with or without abnormal NCS as shown in Table 2.
However, on multiple linear on analysis of all the variables age at diagnosis, NDS, HbA1c, and eGFR (p<0.05) were independently associated with peripheral neuropathy.

**DISCUSSION**

India is home to 69.1 million people with DM and is estimated to have the second highest number of cases of DM in the world after China in 2015. Type 2 Diabetes Mellitus has an insidious onset with asymptomatic preclinical phase, resulting in the presence of microvascular and macrovascular complications even at diagnosis.

In present study we found a high prevalence of peripheral neuropathy of 68.75 % in newly diagnosed type 2 Diabetes mellitus based on NSS/NDS/NCS. Neuropathy was confirmed by NCS in 55% of the patients. Among patients enrolled in present study, 68.75 % had Possible DSPN, 52.5% had Probable DSPN, and 53.75 % had confirmed DSPN and only 3.75% had subclinical DSPN. Percentage of patients diagnosed with neuropathy clinically (52.5%); with both symptoms of neuropathy and signs on examination (probable DSPN) was almost equal to percentage of confirmed DSPN (Abnormal NCS with either symptoms or signs- 53.75%), indicating that clinical examination still remains the main tool for detection of neuropathy.

Many studies in India have shown different prevalence rates of peripheral neuropathy in newly diagnosed Type 2 Diabetes mellitus due to different diagnostic criteria, variable sample size, difference in mean age at diagnosis and ethnicity. In a study done by A. Dutta et al, the prevalence of peripheral neuropathy in newly diagnosed diabetes mellitus was 29%, based on the presence of abnormality in 2 or more of NSS, NDS and NCS. H K Gill et al showed a prevalence of 30% based on presence of abnormality in both NSS and NDS whereas another Indian study showed lower prevalence of peripheral neuropathy of only 13.15%. Present study has found a higher prevalence of peripheral neuropathy in newly diagnosed type 2 DM (68.75%). One reason for such a high prevalence may be the use of abnormality in any of the parameters of NSS, NDS or NCS as criteria to diagnose neuropathy. Studies from Sri Lanka showed a prevalence of peripheral neuropathy of 25.2% and 48.3% in Amsterdam.

In present study, peripheral neuropathy had significant association with age at diagnosis, presence of hypertension, FBS, HbA1c, serum creatinine and eGFR (p<0.05). Multiple linear regression analysis showed age at diagnosis and FPG to be independently associated with peripheral neuropathy. In subgroup analysis of mild, moderate and severe neuropathy, ‘one way between group ANOVA’ showed statistically significant difference in HbA1c, FBS, PPPG and serum creatinine between the groups (p<0.05).

Abnormal NCS had a significant association with age at diagnosis, presence of hypertension, symptoms and signs of neuropathy (NSS, NDS), FPG, PPPG, HbA1c, serum creatinine and eGFR (p<0.05). Positive NCS had a significant association by multiple linear regression analysis showed independent association of age at diagnosis, NDS, HbA1c, and eGFR (p<0.05) with abnormal NCS.

In study by HK Gill et al, regression analysis revealed an increase in risk for DPN with increasing age, duration of symptoms of diabetes prior to presentation and central obesity. On multiple logistic regression analysis, age and duration of symptoms of diabetes were independently associated with DPN. D Bansal et al showed that aging and triglyceride levels were identified as independent risk factors for neuropathy. Similar other studies have shown that age, poor glycaemic control, increasing duration of diabetes, gender, height, body mass index, retinopathy, hypertension, smoking, and alcohol consumption are risk factors.

**CONCLUSION**

Patients with type 2DM have a high prevalence of peripheral neuropathy at diagnosis and very few of them harbour subclinical neuropathy. This study has shown that clinical examination still remains the main tool for detection of neuropathy.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**

1. Ziegler D. Diabetic peripheral Neuropathy. In: Holt R, Cockram C, Flyvbjerg A, Goldstein B. Textbook of Diabetes. 4th ed. West Sussex, UK: Wiley Blackwell. 2010;38:615-25.
2. Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart/New York, 2003;64-82.
3. Vinik AI, Mitchell BD, Leichter SB, Wagner AL, O’Brien AT, George LP. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, eds. Diabetes: Clinical Science in Practice. Cambridge, UK: Cambridge University Press; 1995:221-87.
4. Vinik A, Mehrabayan A. Diabetic neuropathies. Med Clin North Am. 2004;88:947-99
5. Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998;20:169-81.
6. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management...
of foot disease in patients with diabetes. N Engl J Med. 1994;331:854-60.

7. American Diabetic Association. Standards of medical care in diabetes-2018. Diabetes Care. 2018; 41:S1-2.

8. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O’Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose and myoinositol related to sural nerve morphometry. Ann Neurol 1980;8:590-6.

9. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-93.

10. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook Of Endocrinology. 13th ed. 525-35.

11. International Diabetes Federation. IDF Diabetic Atlas. 7th Edition.

12. Dutta A, Naorem S, Singh TP, Wangjam K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetes mellitus. Int J Diab Dev Countries 2005;25:30-33.

13. Gill HK, Yadav SB, Ramesh V, Bhatia E. A prospective study of prevalence and association of peripheral neuropathy in Indian patients with newly diagnosed type2 diabetes mellitus. J Postgrad Med. 2014;60:270-5.

14. Sosale A, Prasanna Kumar KM, Sadikot SM, Nigam A, Bajaj S, Zargar AH, et al. Chronic complications in newly diagnosed patients with Type 2 diabetes mellitus in India. Indian J Endocr Metab. 2014; 18:355-60.

15. Weerasuriya N, Siribaddana S, Dissanayake A, Subasinghe Z, Wariyapola D, Fernando DI. Long-term complications in newly diagnosed Sri Lankan patients with type 2 diabetes mellitus. QJM. 1998; 91:439-43.

16. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: The Hoorn screening study. Diab Care. 2003;26:2604-8.

17. Bansal D, Gudala K, Esam HP, Nayakallu R, Vyamusani RV, Bhansali A. Microvascular Complications and Their Associated Risk Factors in Newly Diagnosed Type 2 Diabetes Mellitus Patients. Int J Chron Dis. 2014;1-7.

18. Ratzmann KP, Raschke M, Gander I, Schimke E. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabet Complications 1991;5:1-5.

19. Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ; North-West diabetes foot care study. Foot ulcer risk is lower in South-Asian and African-Caribbean compared with European diabetic patients in the U.K.: The North-West diabetes foot care study. Diab Care 2005;28:1869-75.

Cite this article as: Bhuyan AK, Appaiah S. Clinical and electrophysiological correlation of peripheral neuropathy in newly diagnosed type 2 diabetes mellitus. Int J Adv Med 2018;5:542-9.